Impact of proton pump inhibitor management committee's multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments

• Published in: BMC health services research Vol. 22; no. 1; p. 417
• Main Authors: Liu, Lu, Yu, Yongqi, Fan, Qingze, Wu, Zhigui, Li, Xiuying, Luo, Hongli
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.03.2022; BioMed Central; BMC
• Subjects: Acid suppressant; Acids; Adolescent; Aged, 80 and over; Ambulatory medical care; Antibiotics; Clinical medicine; Departments; Disease prevention; Drug stores; Emergency medical care; Emergency service; Emergency Service, Hospital; Expenditures; Gastroenterology; Gastroesophageal reflux; Health care expenditures; Health services; Histamine-2 receptor antagonist; Hospitals; Humans; Intervention; Multifaceted intervention; Omeprazole - therapeutic use; Otolaryngology; Outpatients; Patient outcomes; Patients; Pharmacists; Physicians; Prescriptions; Proton pump inhibitor; Proton pump inhibitors; Proton Pump Inhibitors - therapeutic use; Questionnaires; Services; Ulcers; China; Hunan China; Multifaceted intervention; Histamine-2 receptor antagonist; Acid suppressant; Proton pump inhibitor
• ISSN: 1472-6963; 1472-6963
• DOI: 10.1186/s12913-022-07820-x

A nationwide campaign for rational proton pump inhibitor (PPI) use launched in 2015 had a positive impact for hospitalized patients PPI use. But there were few studies focusing on the rational use of PPIs in outpatients. In 2018, the PPI management committee conducted a year-long intervention on the appropriate use of PPIs in outpatient and emergency departments, including clinical pharmacist interventions and stewardship interventions. The purpose of this study was to examine the impact of the PPI management committee's multifaceted interventions by comparing the real-world acid suppressant prescribing patterns for outpatients before (2017) and after intervention (2019) at a Chinese tertiary teaching hospital. Prescriptions containing any acid suppressant in outpatient and emergency departments in baseline (2017) and postintervention (2019) periods were extracted from the hospital information system and the prescription automatic screening system. Acid suppressant prescribing patterns were evaluated based on primary diagnoses and patient demographics. The prescribed acid suppressants stratified using age groups (< 7, 7-17, 18-45, 46-65, 66-85 and > 85 years) were also examined. The utilization rate of acid suppressant in 2017 and 2019 was 2.5% (41,165/1,619,366) and 2.2% (49,550/2,236,471), respectively (P < 0.0001). 60,135 acid suppressant prescriptions were obtained in 2017 and 73,275 in 2019. The rate of acid suppressant prescriptions for the approved indications significantly increased from 62.6% (2017) to 65.4% (2019) (P < 0.0001). Prescriptions diagnosed as abnormal symptoms, signs and clinical manifestations, decreased in 2019 (13.0% vs. 16.5%, P < 0.0001). The most frequently prescribed PPIs differed between 2017 and 2019 (rabeprazole 2017 vs. esomeprazole 2019). Omeprazole was the most common PPI and cimetidine was the most common H RA prescribed to patients aged < 18 years in 2017 and 2019. A total of CNY11.83 million was spent on acid suppressants in 2019, accounting for about 48.7% of total medication cost, increased by 11.3% from 2017 (37.4%). The proportion of acid suppressant prescriptions for approved indications was enhanced after the PPI management committee's multifaceted interventions, but there were still some problems in the selection of acid suppressants.